Cleveland Clinic Diabetes Therapeutics, Technology and Surgery

Cost: $99.00Add to cart

Key Features

6.25 AMA PRA Category I Credits™ Accredited for 6.25 ABIM MOC points. No Post Test!

Topics Covered

Pump updates, dual hormone therapies, sulfonylureas, GLP1 agonists, metformin, and the role of exercise and fasting.  The pathophysiologic impact of COVID-19 will also be explored.  

Learning Objectives

Following this enduring material, the participants will be able to:

1. Describe the efficacy and side effects of therapeutic innovations for type 1 diabetes, including closed-loop insulin pumps, dual hormone therapy and glucagon.
2. Compare the effectiveness of new and emerging therapies for both type 1 and 2 diabetes.
3. Critically appraise the impact of bariatric surgery on patients with type 2 diabetes.
4. Describe options for treating children with type 2 diabetes.
5. Compare the data on effectiveness of diets and exercise in diabetes strategies.
6. Summarize research defining the pathophysiologic impact of nonalcoholic steatohepatitis.
7. Describe how COVID-19 affects the progression of diabetes in infected patients.

Target Audience

This activity is designed for primary care physicians, endocrinologists, diabetes educators, nurses, nurse practitioners, physician assistants, dietitians, and other health care professionals who care for patients with diabetes.

Additional credit info

Release Date: 7/1/21 CME Expiration 6/30/23

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.